130 related articles for article (PubMed ID: 32054892)
1. The anti-tumoral potential of the saporin-based uPAR-targeting chimera ATF-SAP.
Zuppone S; Assalini C; Minici C; Bertagnoli S; Branduardi P; Degano M; Fabbrini MS; Montorsi F; Salonia A; Vago R
Sci Rep; 2020 Feb; 10(1):2521. PubMed ID: 32054892
[TBL] [Abstract][Full Text] [Related]
2. Optimization of construct design and fermentation strategy for the production of bioactive ATF-SAP, a saporin based anti-tumoral uPAR-targeted chimera.
Errico Provenzano A; Posteri R; Giansanti F; Angelucci F; Flavell SU; Flavell DJ; Fabbrini MS; Porro D; Ippoliti R; Ceriotti A; Branduardi P; Vago R
Microb Cell Fact; 2016 Nov; 15(1):194. PubMed ID: 27842546
[TBL] [Abstract][Full Text] [Related]
3. The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated.
Fabbrini MS; Carpani D; Bello-Rivero I; Soria MR
FASEB J; 1997 Nov; 11(13):1169-76. PubMed ID: 9367352
[TBL] [Abstract][Full Text] [Related]
4. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
5. A conjugate between human urokinase and saporin, a type-1 ribosome-inactivating protein, is selectively cytotoxic to urokinase receptor-expressing cells.
Cavallaro U; del Vecchio A; Lappi DA; Soria MR
J Biol Chem; 1993 Nov; 268(31):23186-90. PubMed ID: 8226837
[TBL] [Abstract][Full Text] [Related]
6. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
7. Pichia pastoris as a host for secretion of toxic saporin chimeras.
Lombardi A; Bursomanno S; Lopardo T; Traini R; Colombatti M; Ippoliti R; Flavell DJ; Flavell SU; Ceriotti A; Fabbrini MS
FASEB J; 2010 Jan; 24(1):253-65. PubMed ID: 19786581
[TBL] [Abstract][Full Text] [Related]
8. Urokinase receptor (uPAR) ligand based recombinant toxins for human cancer therapy.
de Virgilio M; Silvestris F
Curr Pharm Des; 2011; 17(19):1979-83. PubMed ID: 21711232
[TBL] [Abstract][Full Text] [Related]
9. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
10. Endocytosis of a chimera between human pro-urokinase and the plant toxin saporin: an unusual internalization mechanism.
Ippoliti R; Lendaro E; Benedetti PA; Torrisi MR; Belleudi F; Carpani D; Soria MR; Fabbrini MS
FASEB J; 2000 Jul; 14(10):1335-44. PubMed ID: 10877826
[TBL] [Abstract][Full Text] [Related]
11. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
13. Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.
Rustamzadeh E; Li C; Doumbia S; Hall WA; Vallera DA
J Neurooncol; 2003 Oct; 65(1):63-75. PubMed ID: 14649886
[TBL] [Abstract][Full Text] [Related]
14. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
[TBL] [Abstract][Full Text] [Related]
15. [Experimental study of anti-metastasis effect of urokinase amino-terminal fragment gene on human breast cancer cells].
Zhu F; Xing G; He F
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):115-7. PubMed ID: 11783013
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor.
Hu XW; Duan HF; Gao LH; Pan SY; Li YM; Xi Y; Zhao SR; Yin L; Li JF; Chen HP; Wu CT
Cancer Biol Ther; 2008 May; 7(5):651-9. PubMed ID: 18245952
[TBL] [Abstract][Full Text] [Related]
17. Expression, purification, and biological characterization of the amino-terminal fragment of urokinase in Pichia pastoris.
Li J; Lin Y; Zhuang H; Hua ZC
J Microbiol Biotechnol; 2013 Sep; 23(9):1197-205. PubMed ID: 23751561
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo anti-tumor effect of Trichobakin fused with urokinase-type plasminogen activator ATF-TBK.
Pham DD; Pham TH; Bui TH; Britikova EV; Britikov VV; Bocharov EV; Usanov SA; Phan VC; Le TBT
Mol Biol Rep; 2024 Jan; 51(1):130. PubMed ID: 38236367
[TBL] [Abstract][Full Text] [Related]
19. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
20. uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
Huber MC; Mall R; Braselmann H; Feuchtinger A; Molatore S; Lindner K; Walch A; Gross E; Schmitt M; Falkenberg N; Aubele M
BMC Cancer; 2016 Aug; 16():615. PubMed ID: 27502396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
